|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|
| Cash flows from operating activities | |||
| Net loss | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation | |||
| Stock-based compensation | |||
| Change in fair value of convertible promissory notes (includes related party amounts of $0 and $13,196, respectively) | |||
| Change in fair value of warrant liabilities - related party | |||
| Non-cash lease costs | |||
| Amortization of operating lease right-of-use assets | |||
| Impairment of property, plant and equipment | |||
| Amortization of debt discount | |||
| Issuance of PIK interest debt | |||
| Acquired in-process research and development - related party | |||
| Issuance (payment) of PIK interest debt | |||
| Acquired in-process research and development | |||
| Net accretion/amortization of premiums and discounts on marketable securities | |||
| Loss on disposal of property and equipment | |||
| Loss on extinguishment of debt | |||
| Changes in operating assets and liabilities: | |||
| Prepaid expenses and other current assets | |||
| Accounts payable, accrued expenses and other long-term liabilities (includes related party amounts of $(33) and $(248), respectively) | |||
| Accrued interest | |||
| Operating lease right-of-use assets and liabilities | |||
| Net cash used in operating activities | |||
| Cash flows from investing activities | |||
| Cash paid for purchased in-process research and development | |||
| Purchases of property and equipment | |||
| Purchases of marketable securities | |||
| Proceeds from sales or maturities of marketable securities | |||
| Net cash provided by (used in) investing activities | |||
| Cash flows from financing activities | |||
| Proceeds from issuance of common stock under share-based compensation arrangements | |||
| Proceeds from issuance of at-the-market offering, net | |||
| Repayment of long-term debt, including fees | |||
| Payment of initial public offering costs | |||
| Proceeds from issuance of common stock in underwritten public offering, net of issuance costs | |||
| Proceeds from issuance of long-term debt, net of issuance costs | |||
| Net cash provided by (used in) financing activities | |||
| Net decrease in cash, cash equivalents and restricted cash | |||
| Cash, cash equivalents and restricted cash-beginning of period | |||
| Cash, cash equivalents and restricted cash-end of period | |||
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest | |||
| Supplemental disclosure of noncash investing and financing activities | |||
| Operating lease | |||
| Unpaid property and equipment purchases | |||
| Conversion of convertible promissory notes and interest into common stock | |||
| Conversion of warrant liability into equity | |||
| Accreted final interest payment fees | |||
| Settlement of ESPP liability in common stock |
Loading...
